Yahoo · Sep 4, 2026
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
NP
NASDAQ · NPCE
NeuroPace, Inc.
Healthcare · Medical - Devices
$14.04
Up+$0.17 (+1.23%)
Updated Sep 12, 2026, 3:02 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 548.85M
- P/E ratio
- -26.65
- Dividend yield
- 0.00%
- 52-week range
- $9.22 – $19.60
- Volume
- 107.48K
- Avg. volume
- 204.94K
Price performance
NPCE price history
1M range · 20 trading sessions · Daily adjusted prices
NPCE closed at $14.04 after 20 trading sessions, down 4.94% for the selected period.
- Last close
- $14.04
- Period change
- -4.94%
- Period low
- $13.87
- Period high
- $15.19
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $14.04 | $14.13 | $13.815 | $14.04 | 107.48K |
| Sep 10, 2026 | $14.46 | $14.465 | $13.825 | $13.87 | 73.03K |
| Sep 9, 2026 | $14.68 | $14.77 | $14.41 | $14.50 | 78.58K |
| Sep 8, 2026 | $14.65 | $15.10 | $14.54 | $14.76 | 105.2K |
| Sep 4, 2026 | $14.62 | $14.90 | $14.47 | $14.90 | 92.32K |
| Sep 3, 2026 | $15.25 | $15.48 | $14.49 | $14.75 | 141.5K |
| Sep 2, 2026 | $14.75 | $15.555 | $14.68 | $15.19 | 163.71K |
| Sep 1, 2026 | $14.70 | $14.86 | $14.515 | $14.74 | 132.83K |
| Aug 31, 2026 | $14.41 | $14.67 | $14.24 | $14.65 | 148.26K |
| Aug 28, 2026 | $14.09 | $14.55 | $13.7643 | $14.41 | 129.42K |
| Aug 27, 2026 | $14.60 | $14.81 | $14.07 | $14.13 | 148.09K |
| Aug 26, 2026 | $14.23 | $14.86 | $14.10 | $14.68 | 172.84K |
| Aug 25, 2026 | $14.04 | $14.27 | $13.9723 | $14.16 | 153.4K |
| Aug 24, 2026 | $14.10 | $14.4799 | $13.96 | $13.99 | 117.66K |
| Aug 21, 2026 | $14.14 | $14.22 | $13.87 | $14.03 | 115.98K |
| Aug 20, 2026 | $14.35 | $14.60 | $13.56 | $14.02 | 191.8K |
| Aug 19, 2026 | $14.45 | $15.28 | $14.45 | $14.64 | 106.61K |
| Aug 18, 2026 | $14.27 | $14.645 | $14.03 | $14.47 | 140.67K |
| Aug 17, 2026 | $14.58 | $14.679 | $14.18 | $14.28 | 197.44K |
| Aug 14, 2026 | $14.46 | $14.80 | $14.29 | $14.77 | 154.96K |
Latest NPCE news
The latest Smart Investors Daily articles mentioning NPCE.
Stock researchCompany · Overview
NPCE research
Overview
Company profile and research snapshot.
Company profile
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $17.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 29, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 23, 2026 | Mizuho | Outperform | — |
| May 15, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 27, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 16, 2025 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 1, 2026
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
MOUNTAIN VIEW, Calif., September 01, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference.
Yahoo · Aug 31, 2026
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
MOUNTAIN VIEW, Calif., August 31, 2026--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
Yahoo · Aug 19, 2026
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
NeuroPace Inc (NPCE) raises full-year guidance on 21.3% RNS revenue growth, while navigating an unexpected FDA request for additional IGE data.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
